James Y Dai, E Georg Luebeck, Ellen T Chang, Christina A Clarke, Earl A Hubbell, Nan Zhang, Stephen W Duffy
BACKGROUND: Late-stage cancer incidence has been proposed as an early surrogate for mortality in randomized controlled trials (RCTs) of cancer screening; however, its validity has not been systematically evaluated across screening RCTs of different cancers. METHODS: We conducted a meta-regression analysis of cancer screening RCTs that reported both late-stage cancer incidence and cancer mortality. Based on a systematic literature review, we included 33 RCTs of screening programs targeting seven cancer types, including lung ( n = 12), colorectal ( n = 8), breast ( n = 5), and prostate ( n = 4), among others...
May 26, 2024: Journal of Medical Screening